Novartis’ innovative drug Noradrena approved for IgA nephropathy in China
August 21, 2025
Source: drugdu
140
On August 20, Novartis Group announced that its innovative product, Noradrena® (atrasentan hydrochloride tablets), has received approval from the National Medical Products Administration (NMPA) for the reduction of proteinuria in adult patients with primary immunoglobulin A nephropathy (IgA nephropathy) at risk of rapid disease progression. Noradrena is reportedly the first non-immunological therapy approved in China for the treatment of IgA nephropathy and the first and currently only highly selective endothelin A (ETA) receptor antagonist for this indication.
https://finance.eastmoney.com/a/202508203489375117.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
